Generic Medicine Info
Indications and Dosage
Allergic conditions
Adult: 8 mg, as necessary, up to tid.
Child: ≥12 yr Same as adult dose.
Renal Impairment
Severe: Contraindicated.
May be taken with or without food.
Severe renal impairment.
Special Precautions
Patient w/ porphyria, epilepsy. Renal impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Anticholinergic effects, GI disturbance, headache, psychomotor impairment, somnolence, dry mouth, rash, blurred vision, urinary retention. Rarely, dizziness, dyspnoea, angioedema.
PO: Z (Adverse pregnancy outcomes (e.g. spontaneous abortions, intrauterine death) have been reported. Should not be used unless benefits outweigh risks.)
Patient Counseling Information
This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.
Drug Interactions
May produce additional mental depression w/ CNS depressants.
Food Interaction
May produce additional mental depression w/ alcohol.
Mechanism of Action: Acrivastine, an alkylamine, is a second generation antihistamine structurally related to triprolidine. It is a competitive antagonist of H1-receptors but lacks anticholinergic effects.
Onset: 15 min.
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: Approx 1.5 hr.
Distribution: Volume of distribution: Approx 0.5-0.8 L/kg. Plasma protein binding: Approx 50%, mainly to albumin.
Metabolism: Minimally metabolised in the liver into its active metabolite, propionic acid.
Excretion: Via urine (84%) and faeces (13%). Elimination half-life: Approx 2-4 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Acrivastine, CID=5284514, (accessed on Jan. 20, 2020)

Store at or below 30°C.
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AX18 - acrivastine ; Belongs to the class of other antihistamines for systemic use.
Anon. Acrivastine and Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 09/08/2016.

Buckingham R (ed). Acrivastine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 09/08/2016.

Joint Formulary Committee. Acrivastine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 09/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Acrivastine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 09/08/2016.

Disclaimer: This information is independently developed by MIMS based on Acrivastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in